Skip to main content
Structure Therapeutics Inc. logo

Structure Therapeutics Inc. — Investor Relations & Filings

Ticker · GPCR ISIN · US86366E1064 US Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2026-05-07 Capital/Financing Update
Country US United States of America
Listing US GPCR

About Structure Therapeutics Inc.

https://structuretx.com/

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company that utilizes a proprietary structure-based drug design platform to discover and develop novel oral small molecule therapeutics. The company focuses on creating more accessible treatments for a range of chronic diseases by targeting G protein-coupled receptors (GPCRs), a well-validated class of drug targets. Its clinical pipeline includes drug candidates for cardiometabolic conditions, such as obesity and type 2 diabetes, as well as pulmonary diseases.

Recent filings

Filing Released Lang Actions
424B5 - Structure Therapeutics Inc. (0001888886) (Filer)
Capital/Financing Update Classification · 87% confidence The document is a prospectus supplement filed under Rule 424(b)(5) to amend an existing at-the-market offering (ATM Prospectus) for American Depositary Shares, increasing the maximum amount to $400 million. It details the terms of equity fundraising, sales agents’ commissions, and capacity remaining under the sales agreement. This is a financing update announcing a share issuance program. Therefore, it falls under Capital/Financing Update.
2026-05-07 English
ARS - Structure Therapeutics Inc. (0001888886) (Filer)
Annual Report
2026-04-23 English
8-K - Structure Therapeutics Inc. (0001888886) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 15, 2026, for Structure Therapeutics Inc. The content focuses on the appointment of a new Chief Operating Officer and General Counsel, Matthew Lang, detailing his background, employment terms, and compensation awards. The document does not contain financial statements or quarterly/yearly financial results but rather announces a change in senior management. The presence of Item 5.02 (Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers) confirms this is a management change announcement. Therefore, the document fits the category of Board/Management Information (MANG). The document length (9638 characters) is sufficient to be a full filing, not just an announcement of a report. Hence, the classification is MANG with high confidence.
2026-04-15 English
10-K - STRUCTURE THERAPEUTICS INC. (0001888886) (Filer)
Annual Report FY 2025
2026-02-26 English
8-K - STRUCTURE THERAPEUTICS INC. (0001888886) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 26, 2026, reporting the results of operations and financial condition for the fourth quarter ended December 31, 2025. It includes a press release as Exhibit 99.1 announcing the financial results. The text explicitly states that the press release is furnished and incorporated by reference, and the document is relatively short (4616 characters). This indicates it is a current report announcing financial results rather than the full earnings release or detailed financial statements. Form 8-K filings with Item 2.02 are typically used to announce earnings results in a summarized form. Therefore, the document fits best under the Earnings Release (ER) category, which covers initial announcements of quarterly financial results with key highlights only.
2026-02-26 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.